BRIEF published on 04/16/2024 at 13:05, 2 years 6 months ago CureVac et MD Anderson collaborent sur des vaccins innovants contre le cancer Technologie ARNm CureVac MD Anderson Vaccins Contre Le Cancer Collaboration Biopharmaceutique
PRESS RELEASE published on 04/16/2024 at 13:00, 2 years 6 months ago CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines CureVac and MD Anderson announce strategic collaboration to develop mRNA-based cancer vaccines, leveraging respective expertise to address unmet medical needs in hematological and solid tumors Clinical Research Collaboration CureVac MD Anderson MRNA-based Cancer Vaccines
BRIEF published on 04/04/2024 at 13:05, 2 years 7 months ago CureVac Reports Positive Phase 2 Results for Influenza Vaccine in Collaboration with GSK GSK MRNA Technology CureVac Influenza Vaccine Phase 2 Trial
BRIEF published on 04/04/2024 at 13:05, 2 years 7 months ago CureVac annonce des résultats positifs de phase 2 pour son vaccin contre la grippe en collaboration avec GSK GSK Technologie ARNm CureVac Vaccin Contre La Grippe Essai De Phase 2
PRESS RELEASE published on 04/04/2024 at 13:00, 2 years 7 months ago CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK CureVac announces positive Phase 2 interim results for seasonal influenza vaccine in collaboration with GSK, showing strong antibody titers and safety profile GSK CureVac Phase 2 Seasonal Influenza Vaccine MRNA
PRESS RELEASE published on 11/01/2023 at 13:00, 3 years ago CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
PRESS RELEASE published on 09/28/2023 at 13:00, 3 years 1 month ago CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
PRESS RELEASE published on 09/12/2023 at 13:15, 3 years 1 month ago CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
PRESS RELEASE published on 09/12/2023 at 13:00, 3 years 1 month ago CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
PRESS RELEASE published on 08/17/2023 at 13:00, 3 years 2 months ago CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Published on 11/05/2026 at 14:31, 50 minutes ago First Breach Close-Quarters Strike (CQS) Drone Successfully Completes Full Mission Profile
Published on 11/05/2026 at 14:20, 1 hour 1 minute ago Polaris Renewable Energy Declares Quarterly Dividend
Published on 11/05/2026 at 14:15, 1 hour 6 minutes ago Loar Holdings Inc. Reports Q3 2026 Record Results and Upward Revision to 2026 Outlook and Full Year 2027 Outlook
Published on 11/05/2026 at 14:00, 1 hour 21 minutes ago Horizon Aircraft Signs MOU With Constance Lake First Nation to Bring Lifesaving Medical Aircraft to Remote and Isolated Indigenous Communities
Published on 11/05/2026 at 15:10, 10 minutes ago Center for Creative Leadership Names Patrick Mullane President and Chief Executive Officer
Published on 11/05/2026 at 14:58, 23 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/05/2026 at 15:01, 19 minutes ago Chiffre d'Affaires du 1er semestre de l'exercice 2026/2027
Published on 11/05/2026 at 10:16, 5 hours 4 minutes ago Accélération confirmée au troisième trimestre 2026 Tous les métiers en croissance, chiffre d’affaires en progression de +6,5 %
Published on 11/05/2026 at 10:16, 5 hours 4 minutes ago Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%
